The effect of itraconazole on the vaginal candidiasis under different immunity conditions in mice.
To study the effect of itraconazole on the vaginal candidiasis caused by Candida under different immunity conditions, the fungal vaginitis model was established in female ICR mice by intravaginal inoculation of suspension of C. albicans after the animal had been pretreated with estradiol or dexamethasone. Mice were divided at random into different groups and then treated with itraconazole or IFN-gamma given by gastrolavage. The burden of the fungus in the vaginal lavage fluids in the mice of the different groups was measured dynamically at different time points after the beginning of the drug treatment. The difference in the effect of itraconazole on the vaginal candidiasis between normal immune system group (group A) and control group (group D) was statistically significant (P<0.01). The difference in the efficacy of itraconazole among immunosuppressed group (group E), immuno-regulated group (group F) and the control group (group G) was statistically significant (P<0.01). But on the 5th, 6th, 7th, 9th, 11th day after the inoculation the average level of colony forming unit (CFU) of groups A, E and F showed no statistically significant difference (P>0.05). It is concluded that the efficacy of itraconazole in the treatment of the vaginal candidiasis under different immunity conditions (groups A, E and F) in mice were all good, but there was no difference in the anti-fungal effect of itraconazole among the three groups.
Ouyang
Weixiang
W
Department of Gynecology and Obstetrics, Huazhong University of Science and Technology, Wuhan, 430022, China. OY6222@yahoo.com.cn
Chen
Shanjuan
S
Li
Shaohua
S
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002176:Candida albicans / Q000187:drug effects; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology; D003907:Dexamethasone / Q000008:administration & dosage; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D016867:Immunocompromised Host; D007371:Interferon-gamma / Q000627:therapeutic use; D017964:Itraconazole / Q000627:therapeutic use*; D051379:Mice; D008813:Mice, Inbred ICR; D011897:Random Allocation
D000935:Antifungal Agents; D004967:Estrogens; D017964:Itraconazole; D003907:Dexamethasone; D007371:Interferon-gamma